📊 INDP Key Takeaways
Is Indaptus Therapeutics, Inc. (INDP) a Good Investment?
Indaptus Therapeutics is a pre-revenue biotech company with no income generation, burning $7M annually in operating cash against only $1.5M in cash reserves, implying severe financial distress within 2-3 months. Negative net income of -$2.5M, zero revenue, and stockholders' equity of just $1.2M indicate the company lacks financial runway for continued operations without immediate capital infusion or transformative clinical success.
Indaptus Therapeutics appears to be a pre-revenue clinical-stage biotech with no commercial revenue, persistent operating losses, and deeply negative returns on equity and assets. While the balance sheet has no long-term debt and still holds cash, the current cash balance is materially below the recent annual operating cash burn, implying meaningful financing risk and weak growth quality unless clinical progress materially improves funding access or operating efficiency.
Why Buy Indaptus Therapeutics, Inc. Stock? INDP Key Strengths
- Zero long-term debt reduces fixed obligations
- Current ratio of 2.34x shows short-term liquidity is not immediately critical
- EPS deterioration moderation (52% YoY improvement, though still negative) suggests potential operational stabilization efforts
- Debt-free capital structure reduces financial leverage risk
- Cash represents the majority of total assets, providing near-term operating flexibility
- Net loss and diluted EPS improved year over year, indicating some expense moderation
INDP Stock Risks: Indaptus Therapeutics, Inc. Investment Risks
- Critical cash runway: $1.5M cash against $7M annual operating burn leaves approximately 2-3 months of operations before insolvency
- Zero revenue generation indicates no commercial traction or approved products
- Deeply negative equity (-203.6% ROE) signals potential shareholder dilution or capital restructuring risk
- Rapidly deteriorating net income (-38.8% YoY) despite modest EPS improvement reflects worsening fundamentals masked by share dilution
- Minimal stockholders' equity of $1.2M provides no cushion for operational losses
- No revenue base means the business is entirely dependent on external financing and pipeline execution
- Operating cash outflow materially exceeds cash on hand, creating elevated dilution or capital raise risk
- Very low equity base and extremely negative ROE/ROA reflect weak underlying financial sustainability
Key Metrics to Watch
- Cash balance trend and monthly burn rate (critical for survival assessment)
- Announcements of capital raises, financing, or partnership deals
- Clinical trial progress or regulatory milestone announcements affecting asset value
- Quarterly operating cash burn relative to cash and equivalents
- Clinical pipeline milestones and any resulting revenue partnerships or non-dilutive funding
Indaptus Therapeutics, Inc. (INDP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.34x current ratio provides a solid financial cushion.
INDP Profit Margin, ROE & Profitability Analysis
INDP vs Healthcare Sector: How Indaptus Therapeutics, Inc. Compares
How Indaptus Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Indaptus Therapeutics, Inc. Stock Overvalued? INDP Valuation Analysis 2026
Based on fundamental analysis, Indaptus Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Indaptus Therapeutics, Inc. Balance Sheet: INDP Debt, Cash & Liquidity
INDP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Indaptus Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-44.96 indicates the company is currently unprofitable.
INDP Revenue Growth, EPS Growth & YoY Performance
Indaptus Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
INDP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Indaptus Therapeutics, Inc. (CIK: 0001857044)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INDP
What is the AI rating for INDP?
Indaptus Therapeutics, Inc. (INDP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INDP's key strengths?
Claude: Zero long-term debt reduces fixed obligations. Current ratio of 2.34x shows short-term liquidity is not immediately critical. ChatGPT: Debt-free capital structure reduces financial leverage risk. Cash represents the majority of total assets, providing near-term operating flexibility.
What are the risks of investing in INDP?
Claude: Critical cash runway: $1.5M cash against $7M annual operating burn leaves approximately 2-3 months of operations before insolvency. Zero revenue generation indicates no commercial traction or approved products. ChatGPT: No revenue base means the business is entirely dependent on external financing and pipeline execution. Operating cash outflow materially exceeds cash on hand, creating elevated dilution or capital raise risk.
What is INDP's revenue and growth?
Indaptus Therapeutics, Inc. reported revenue of N/A.
Does INDP pay dividends?
Indaptus Therapeutics, Inc. does not currently pay dividends.
Where can I find INDP SEC filings?
Official SEC filings for Indaptus Therapeutics, Inc. (CIK: 0001857044) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INDP's EPS?
Indaptus Therapeutics, Inc. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INDP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Indaptus Therapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INDP stock overvalued or undervalued?
Valuation metrics for INDP: ROE of -203.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INDP stock in 2026?
Our dual AI analysis gives Indaptus Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INDP's free cash flow?
Indaptus Therapeutics, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $3.9K.
How does INDP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -203.6% (avg: 15%), current ratio 2.34 (avg: 2).